NO976063D0 - Fremgangsmåte for behandling av diabetes - Google Patents

Fremgangsmåte for behandling av diabetes

Info

Publication number
NO976063D0
NO976063D0 NO976063A NO976063A NO976063D0 NO 976063 D0 NO976063 D0 NO 976063D0 NO 976063 A NO976063 A NO 976063A NO 976063 A NO976063 A NO 976063A NO 976063 D0 NO976063 D0 NO 976063D0
Authority
NO
Norway
Prior art keywords
diabetes
procedure
treatment
Prior art date
Application number
NO976063A
Other languages
English (en)
Other versions
NO976063L (no
Inventor
Thomas W Stephens
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21692725&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO976063(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO976063D0 publication Critical patent/NO976063D0/no
Publication of NO976063L publication Critical patent/NO976063L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
NO976063A 1995-06-30 1997-12-23 Fremgangsmåte for behandling av diabetes NO976063L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71895P 1995-06-30 1995-06-30
PCT/US1996/010983 WO1997002004A2 (en) 1995-06-30 1996-06-26 Methods for treating diabetes

Publications (2)

Publication Number Publication Date
NO976063D0 true NO976063D0 (no) 1997-12-23
NO976063L NO976063L (no) 1998-02-16

Family

ID=21692725

Family Applications (1)

Application Number Title Priority Date Filing Date
NO976063A NO976063L (no) 1995-06-30 1997-12-23 Fremgangsmåte for behandling av diabetes

Country Status (14)

Country Link
US (1) US5756461A (no)
EP (1) EP0836479A2 (no)
JP (1) JPH11508895A (no)
KR (1) KR19990028388A (no)
CN (1) CN1195293A (no)
AU (1) AU695934B2 (no)
CA (1) CA2225454A1 (no)
CZ (1) CZ416797A3 (no)
EA (1) EA199800104A1 (no)
HU (1) HUP9802609A2 (no)
IL (1) IL122718A0 (no)
NO (1) NO976063L (no)
PL (1) PL324284A1 (no)
WO (1) WO1997002004A2 (no)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
EP0759441A3 (en) * 1995-06-30 1999-06-30 Eli Lilly And Company Methods of treating neuropeptide Y-associated conditions
ZA965346B (en) * 1995-06-30 1997-12-24 Lilly Co Eli Methods of treating neuropeptide Y-associated conditions.
US6001816A (en) * 1996-06-20 1999-12-14 Merck & Co., Inc. Gene therapy for leptin deficiency
US6277592B1 (en) * 1996-07-31 2001-08-21 Purina Mills, Inc. Porcine leptin protein, nucleic acid sequences coding therefor and uses thereof
CZ90999A3 (cs) * 1996-09-20 1999-06-16 Hoechst Aktiengesellschaft Farmaceutický přípravek obsahující antagonistu leptinu vhodný pro léčení inzulínové rezistence u diabetes mellitus II. typu
EP0996459B1 (en) * 1997-01-07 2005-09-21 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
IL120733A0 (en) * 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
KR20010013414A (ko) * 1997-06-06 2001-02-26 피터 기딩스 당뇨병의 치료를 위한 렙틴 길항제의 용도
WO1999006059A2 (en) * 1997-07-30 1999-02-11 Board Of Regents, The University Of Texas System Methods and compositions relating to no-mediated cytotoxicity
EP1489100B1 (en) 1997-12-08 2016-06-15 Merck Patent GmbH Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US5866547A (en) 1998-01-20 1999-02-02 Beth Israel Deaconess Medical Center Methods of neuroendocrine regulation of affective disorders
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
WO1999044598A2 (en) * 1998-03-03 1999-09-10 Board Of Regents, The University Of Texas System Methods for inhibiting βcell apoptosis
JP4215857B2 (ja) * 1998-03-26 2009-01-28 裕 大村 学習・記憶能力改善剤
RU2229305C2 (ru) * 1998-04-15 2004-05-27 Лексиген Фармасьютикэлс Корпорейшн Усиление иммунных ответов, опосредованных белками, слитыми из антитела и цитокина, посредством совместного введения ингибитора ангиогенеза
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
WO2000020872A1 (en) * 1998-10-02 2000-04-13 Amgen Inc. Method to determine a predisposition to leptin treatment
US6716810B1 (en) * 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
US6603058B1 (en) 1998-12-09 2003-08-05 Oklahoma Medical Research Foundation Non-human animal model for obesity and uses thereof
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US6475984B2 (en) * 1999-04-29 2002-11-05 The Nemours Foundation Administration of leptin
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
JP4793971B2 (ja) 1999-08-09 2011-10-12 メルク パテント ゲーエムベーハー 複合サイトカイン−抗体複合体
EP1228214A2 (en) 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietin forms with improved properties
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
DE60129695T2 (de) * 2000-06-29 2008-06-05 Merck Patent Gmbh Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
AU2002248571B2 (en) * 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
PT1383785E (pt) * 2001-05-03 2011-06-28 Merck Patent Gmbh Anticorpo recombinante específico de tumores e utilização deste
PT2219031E (pt) * 2001-10-22 2013-05-17 Amgen Inc Uso de leptina para tratamento de lipoatrofia humana e método para determinar predisposição ao referido tratamento
PT1454138E (pt) 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
US6899892B2 (en) * 2001-12-19 2005-05-31 Regents Of The University Of Minnesota Methods to reduce body fat
CN100432105C (zh) * 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
EP1718665B1 (en) 2004-02-11 2013-04-10 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
BRPI0606992A2 (pt) 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
ES2258923B1 (es) * 2005-02-23 2007-11-01 Universitat De Les Illes Balears Uso de la leptina para la prevencion del exceso de peso corporal y composicion que contiene leptina.
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
EP2330124B1 (en) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
US8716220B2 (en) * 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
US8642543B2 (en) * 2005-09-07 2014-02-04 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
WO2010118384A2 (en) 2009-04-10 2010-10-14 Amylin Pharmaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
CN102552225A (zh) * 2010-01-25 2012-07-11 四川省中医药科学院 四氢姜黄素的新用途
US20110218141A1 (en) * 2010-03-03 2011-09-08 Hamrick Mark W Leptin therapy to increase muscle mass and to treat muscle wasting conditions
ES2630031T3 (es) * 2010-09-28 2017-08-17 Aegerion Pharmaceuticals, Inc. Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
US10046013B2 (en) * 2011-03-08 2018-08-14 The Trustees Of The University Of Pennsylvania Engineered bacteria for oral delivery of glucoregulatory proteins
ES2732475T3 (es) 2011-07-08 2019-11-22 Aegerion Pharmaceuticals Inc Polipéptidos modificados por ingeniería genética que tienen una duración potenciada de la acción y una inmunogenicidad reducida
RU2650646C2 (ru) 2012-09-27 2018-04-16 Дзе Чилдрен'З Медикал Сентер Корпорейшн Соединения, предназначенные для лечения ожирения, и способы их применения
SI3074033T1 (sl) 2013-11-26 2019-03-29 The Children's Medical Center Corporation Spojine za zdravljenje debelosti in postopki njihove uporabe
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CA3036551A1 (en) 2016-09-12 2018-03-15 Aegerion Pharmaceuticals, Inc. Methods of detecting anti-leptin neutralizing antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof

Also Published As

Publication number Publication date
CZ416797A3 (cs) 1998-06-17
HUP9802609A2 (hu) 1999-03-29
JPH11508895A (ja) 1999-08-03
AU695934B2 (en) 1998-08-27
PL324284A1 (en) 1998-05-11
NO976063L (no) 1998-02-16
AU6479596A (en) 1997-02-05
WO1997002004A3 (en) 1997-05-22
CN1195293A (zh) 1998-10-07
US5756461A (en) 1998-05-26
MX9800133A (es) 1998-03-29
WO1997002004A2 (en) 1997-01-23
KR19990028388A (ko) 1999-04-15
EA199800104A1 (ru) 1998-10-29
IL122718A0 (en) 1998-08-16
EP0836479A2 (en) 1998-04-22
CA2225454A1 (en) 1997-01-23

Similar Documents

Publication Publication Date Title
NO976063D0 (no) Fremgangsmåte for behandling av diabetes
NO965377L (no) Indolinonforbindelser for behandling av sykdommer
FI973292A7 (fi) Substituoituja isoksatsoleja tulehduksen hoitamiseksi
NO961006D0 (no) Fosfonomononukleinsyrer, fremgangsmåter for fremstilling derav og anvendelse av forbindelsene
NO952573D0 (no) Blandinger for behandling av diabetiske komplikasjoner
NO991955L (no) FremgangsmÕte for behandling av hydrokarboner
NO982172D0 (no) Anvendelse av epinastin for behandling av smerter
NO986052D0 (no) Antikonvulsive derivater for behandling av fedme
FI964874A0 (fi) Vihannesten käsittely
NO963785D0 (no) Fremgangsmåte for behandling av 5HT2B-reseptor-relaterte betingelser
FI952721L (fi) Aine maksa-sappi-sairauksien hoitamiseksi
LV11615A (lv) Amidi ar arstnieciskam ipasibam
FI962249A7 (fi) Substituoituja pyratsolyylibentseenisulfonamideja tulehduksen hoitoa varten
FI973281L (fi) Menetelmä tiettyjen atsasykloheksapeptidien valmistamiseksi
NO20022087D0 (no) Fremgangsmåte for behandling av diabetes
NO990225D0 (no) Medikamenter for behandling av hyperfosfatemi
FI962370A0 (fi) Laite tissuen valmistamiseksi
NO953254D0 (no) Substituerte azolonderivater for behandling av sykdommer forårsaket av helikobakter
NO975718L (no) Behandling av insulinresistens
AU7310896A (en) Use of nitroflavonoids for the treatment of anxiety
NO982911D0 (no) FremgangsmÕte for behandling av depresjon
NO982582D0 (no) FremgangsmÕte for behandling av smerte
NO973366D0 (no) Fremgangsmåte for behandling av multippel sklerose
NO913117L (no) Fremgangsmaate for behandling av benoedeleggende sykdommer.
NO982562D0 (no) Sammensetning for behandling av smerte